Porin A-specific antibody avidity in patients who are convalescing from meningococcal B disease

Pediatric Research

Volumn 58, Issue 1, 2005, Pages 149-152

  Vermont, Clementien L ^a,b   Van Dijken, Harry H ^a   De Groot, Ronald ^b   Van Den Dobbelsteen, Germie P J M ^a  

^a NETHERLANDS VACCINE INSTITUTE   (Netherlands)

^b SOPHIA CHILDREN S HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2; IMMUNOGLOBULIN G3; IMMUNOGLOBULIN G4; PORIN; PORIN A; UNCLASSIFIED DRUG;

ADOLESCENT; ANTIBODY SPECIFICITY; ANTIBODY TITER; ARTICLE; BLOOD SAMPLING; CHILD; CLINICAL ARTICLE; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; INFANT; MENINGOCOCCOSIS; NEISSERIA MENINGITIDIS; PRIORITY JOURNAL; SEROTYPE;

ANTIBODY AFFINITY; CHILD; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; IMMUNOGLOBULIN G; MENINGOCOCCAL INFECTIONS; MENINGOCOCCAL VACCINES; MUTATION; NEISSERIA MENINGITIDIS, SEROGROUP B; PORINS; SEPSIS; TIME FACTORS;

EID: 22044456253     PISSN: 00313998     EISSN: None     Source Type: Journal    
DOI: 10.1203/01.PDR.0000156372.13569.08     Document Type: Article

References (21)

1. Wedege E, Hoiby EA, Rosenqvist E, Bjune G 1998 Immune responses against major outer membrane antigens of Neisseria meningitidis in vaccinees and controls who contracted meningococcal disease during the Norwegian serogroup B protection trial. Infect Immun 66:3223-3231
2. Wedege E, Bolstad K, Wetzler LM, Guttormsen H 2000 IgG antibody levels to meningococcal porins in patient sera: comparison of immunoblotting and ELISA measurements. J Immunol Methods 244:9-15
3. Pollard AJ, Galassini R, van der Voort EM, Booy R, Langford P, Nadel S, Ison C, Kroll JS, Poolman J, Levin M 1999 Humoral immune responses to Neisseria meningitidis in children. Infect Immun 67:2441-2451
4. Pollard AJ, Levin M 2000 Production of low-avidity antibody by infants after infection with serogroup B meningococci. Lancet 356:2065-2066
5. Bjune G, Hoiby EA, Gronnesby JK, Arnesen O, Fredriksen JH, Halstensen A, Holten E, Lindbak AK, Nokleby H, Rosenqvist E, et al. 1991 Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway. Lancet 338:1093-1096
6. Boslego J, Garcia J, Cruz C, Zollinger W, Brandt B, Ruiz S, Martinez M, Arthur J, Underwood P, Silva W, Moran E, Hankins W, Gilly J, Mays J 1995 Efficacy, safety, and immunogenicity of a meningococcal group B (15:P1.3) outer membrane protein vaccine in Iquique, Chile. Chilean National Committee for Meningococcal Disease. Vaccine 13:821-829
7. de Moraes JC, Perkins BA, Camargo MC, Hidalgo NT, Barbosa HA, Sacchi CT, Landgraf IM, Gattas VL, Vasconcelos Hde G, Gral IM, et al. 1992 Protective efficacy of a serogroup B meningococcal vaccine in Sao Paulo, Brazil. Lancet 340:1074-1078
8. de Kleijn E, van Eijndhoven L, Vermont C, Kuipers B, van Dijken H, Rumke H, de Groot R, van Alphen L. van den Dobbelsteen G 2001 Serum bactericidal activity and isotype distribution of antibodies in toddlers and schoolchildren after vaccination with RIVM hexavalent PorA vesicle vaccine. Vaccine 20:352-358
9. Vermont CL, van Dijken HH, van Limpt CJ, de Groot R, van Alphen L, van Den Dobbelsteen GP 2002 Antibody avidity and immunoglobulin G isotype distribution following immunization with a monovalent meningococcal B outer membrane vesicle vaccine. Infect Immun 70:584-590
10. Longworth E, Borrow R, Goldblatt D, Balmer P, Dawson M, Andrews N, Miller E, Cartwright K 2002 Avidity maturation following vaccination with a meningococcal recombinant hexavalent PorA OMV vaccine in UK infants. Vaccine 20:2592-2596
11. Goldblatt D, Borrow R, Miller E 2002 Natural and vaccine-induced immunity and immunologic memory to Neisseria meningitidis serogroup C in young adults. J Infect Dis 185:397-400
12. Joseph H, Miller E, Dawson M, Andrews N, Feavers I, Borrow R 2001 Meningococcal serogroup A avidity indices as a surrogate marker of priming for the induction of immunologic memory after vaccination with a meningococcal A/C conjugate vaccine in infants in the United Kingdom. J Infect Dis 184:661-662
13. Richmond P, Borrow R, Goldblatt D, Findlow J, Martin S, Morris R, Cartwright K, Miller E 2001 Ability of 3 different meningococcal C conjugate vaccines to induce immunologic memory after a single dose in UK toddlers. J Infect Dis 183:160-163
14. van der Voort ER, van der Ley P, van der Biezen J, George S, Tunnela O, van Dijken H, Kuipers B, Poolman J 1996 Specificity of human bactericidal antibodies against PorA P1.7,16 induced with a hexavalent meningococcal outer membrane vesicle vaccine. Infect Immun 64:2745-2751
15. Guttormsen HK, Wetzler LM, Naess A 1993 Humoral immune response to the class 3 outer membrane protein during the course of meningococcal disease. Infect Immun 61:4734-4742
16. Santos GF, Deck RR, Donnelly J, Blackwelder W, Granoff DM 2001 Importance of complement source in measuring meningococcal bactericidal titers. Clin Diagn Lab Immunol 8:616-623
17. Welsch IA, Moe GR, Rossi R, Adu-Bobie J, Rappuoli R, Granoff DM 2003 Antibody to genome-derived neisserial antigen 2132. a Neisseria meningitidis candidate vaccine, confers protection against bacteremia in the absence of complement-mediated bactericidal activity. J Infect Dis 188:1730-1740
18. Welsch JA, Granoff DM 2004 Naturally acquired passive protective activity against Neisseria meningitidis Group C in the absence of serum bactericidal activity. Infect Immun 72:5903-5909
19. Halstensen A, Lehmann AK, Guttormsen HK, Vollset SE, Bjune G, Naess A 1991 Serum opsonins to serogroup B meningococci after disease and vaccination. NIPH Ann 14:157-165, discussion 166-167
20. Usinger WR, Lucas AH 1999 Avidity as a determinant of the protective efficacy of human antibodies to pneumococcal capsular polysaccharides. Infect Immun 67:2366-2370
21. Lucas AH, Granoff DM 1995 Functional differences in idiotypically defined IgG1 anti-polysaccharide antibodies elicited by vaccination with Haemophilus influenzae type B polysaccharide-protein conjugates. J Immunol 154:4195-4202